ISSN: 1859 - 2872
The relationship between plasma CTLA-4 concentration and liver disease progression stages in patients with chronic hepatitis B virus infection
Main Article Content
Keywords
Abstract
Objective: The immune checkpoint molecule CTLA-4 inhibits the activation of T lymphocytes, which plays a crucial role in the pathogenesis of various infectious diseases and cancers. We conducted a study to evaluate the relationship between sCTLA-4 levels and liver disease progression in HBV infectious patients. Subject and method: sCTLA-4 levels were quantified using commercial ELISA kits in a cross-sectional study with a control group including chronic hepatitis (n = 74), liver cirrhosis (n = 76), hepatocellular carcinoma (n = 72), and 72 healthy individuals. Result: Plasma sCTLA-4 levels were higher in HBV patients than in the control group, increasing progressively from the chronic hepatitis, cirrhosis, and hepatocellular carcinoma groups. The plasma level of sCTLA-4 was positively correlated with hepatic inflammation markers such as ALT, AST, and Fib-4. Conclusion: Elevated sCTLA-4 levels are seen in advanced stages of liver disease associated with hepatitis B virus infection. Soluble CTLA-4 may serve as a complementary circulatory immune marker in the management of patients with chronic HBV infection.
Article Details
References
2. Chang JJ, Lewin SR (2007) Immunopathogenesis of hepatitis B virus infection. ImmunolCell Biol 85(1): 16-23. doi:10.1038/sj.icb.7100009
3. Bertoletti A, Ferrari C (2016) Adaptive immunity in HBV infection. J Hepatol 64(1):S71-S83. doi:10.1016/j.jhep.2016.01.026
4. Rehermann B (2013) Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19(7): 859-868. doi:10.1038/nm.3251
5. Fisicaro P, Valdatta C, Massari M et al (2012) Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143(6): 1576-1585 e4. doi:10.1053/j.gastro.2012.08.041
6. Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nature Reviews Immunology 20(11): 651-668. doi:10.1038/s41577-020-0306-5
7. Wykes MN LS (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2): 91-104. doi:10.1038/nri.2017.112
8. Schurich A, Khanna P, Lopes AR et al (2011) Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53(5): 1494-503. doi:10.1002/hep.24249
9. Dyck L, KHG M (2017) Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol 47(5): 765-779. doi:10.1002/eji.201646875
10. Khan M, Arooj S, (2021) Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy. Front Immunol. 2021;12(651634)doi:10.3389/fimmu.2021.651634
11. Kennedy PT, Saulters EL, Duckworth AD et al (2024) Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol Ther 32(2): 457-468. doi:10.1016/j.ymthe.2023.11.028
12. Bộ Y tế (2019) Quyết đinh về việc ban hành hướng dẫn chẩn đoán và điều trị bệnh viêm gan virus B.
13. Bộ Y tế (2020) Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan, tr. 11-14.
14. King HAD SR L (2024) Immune checkpoint inhibitors in infectious disease. Immunol Rev 328(1): 350-371. doi:10.1111/imr.13388
15. Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18(3): 151-166. doi:10.1038/s41575-020-00372-7
16. Cao J, Zhang L, Huang S et al (2011) Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb Pathog 51(4): 262-267. doi:10.1016/j.micpath.2011.06.003
17. Darmadi D, Lindarto D, Siregar J et al (2023) Association between serum cytotoxic t lymphocyte antigen (CTLA)-4 level and disease progression in patients with chronic hepatitis B. Med Arch. 77(2): 142-145. doi:10.5455/medarh.2023.77.142-145
18. Wang D, Du Q, Luo G et al (2017) Aberrant production of soluble inducible T cell co‑stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B. Mol Med Rep 16(6): 8556-8562. doi:10.3892/mmr.2017.7630.
19. Wang L, Li N, Fan X et al (2020) Circulating CTLA-4 levels and CTLA4 polymorphisms associate with disease condition and progression and hepatocellular carcinoma patients' survival in chronic hepatitis B virus infection. Int Immunopharmacol 82(106377)doi:10.1016/j.intimp.2020.106377
20. European Association for the Study of the Liver (2017) Electronic address: Easloffice@easloffice.eu EAftSotL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67(2): 370-398.
Article Sidebar
